Evidence map›Paper›PMID 27872957›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2017

Utility of

Frank I Lin, E M Gonzalez, S Kummar, K Do, J Shih, S Adler, K A Kurdziel, A Ton, B Turkbey, P M Jacobs and 6 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Frank I LinCancer Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA. frank.lin2@nih.gov.
E M GonzalezMolecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.
S KummarDivision of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
K DoDivision of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
J ShihBiometric Research Program, National Cancer Institute, NIH, Bethesda, MD, USA.
S AdlerClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, 21702, USA.
K A KurdzielMolecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.
A TonMolecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.
B TurkbeyMolecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.
P M JacobsCancer Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
S BhattacharyyaFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA.
A P ChenEarly Clinical Trials Development Program, DCTD, National Cancer Institute, Bethesda, MD, USA.
J M CollinsDivision of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
J H DoroshowDivision of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
P L ChoykeMolecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.
M L LindenbergMolecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.
National Cancer Institute · USCenter for Cancer Research · USLeidos (United States) · US

Funding

Phase 01 Clinical TrialsZIABC011078 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$9.0M
Lymphatic ImagingZ01BC010654 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2005 to 2008
$1.1M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC010654NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundZ-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6.

methodsFifteen patients were recruited from a parent therapeutic trial of Z-endoxifen and underwent imaging with

resultsStatistically significant changes (p = 0.0078) in standard uptake value (SUV)-Max were observed between the baseline and follow-up scans as early as 1 day post drug administration.

conclusionF-FES PET imaging could serve as a pharmacodynamic biomarker for patients treated with ER-directed therapy.

Indexed as

Positron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedBreast NeoplasmsBreast Neoplasms, MaleEstradiolEstrogen AntagonistsFemaleGenital Neoplasms, FemaleHumansMaleMiddle AgedReceptors, EstrogenTamoxifen16-fluoroestradiol4-hydroxy-N-desmethyltamoxifenEstradiolEstrogen AntagonistsRadiopharmaceuticalsReceptors, EstrogenTamoxifen18F-FESFluoroestradiolPharmacodynamic markerPositron emission tomography (PET)Z-endoxifen

Identifiers

PMID27872957
PMCPMC7886184
OpenAlexW2556497036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.